Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

Bone Marrow Transplantation
K van BesienF Cabanillas

Abstract

The purpose of the study was to evaluate in patients with recurrent intermediate-grade NHL, the tolerance to and efficacy of an intensive salvage regimen consisting of high doses of ifosfamide, etoposide and mitoxantrone with G-CSF support, followed by autologous stem cell transplantation and to identify prognostic factors for survival in patients with recurrent aggressive lymphoma. Patients with recurrent intermediate-grade NHL under the age of 60 years were eligible. Induction consisted of ifosfamide 10 g/m(2) and etoposide 900 mg/m(2) with G-CSF 5 microg/kg twice a day. Upon recovery, patients underwent stem cell apheresis. Patients achieving complete remission (CR) underwent autologous stem cell transplantation using BEAM conditioning. Those with partial remission (PR) received treatment with ifosfamide 10 g/m(2), mitoxantrone 20 mg/m(2) and G-CSF 5 microg/kg. Those with CR received BEAM, those with PR received cyclophosphamide 4.5 g/m(2), etoposide 1200 mg/m(2) and cisplatin 135 mg/m(2) with stem cell rescue followed by BEAM. Antibiotic prophylaxis was given with all treatment cycles. The results were compared with those obtained in a prior study that used MINE-ESHAP salvage. Forty-four patients with recurrent intermediate...Continue Reading

References

Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S I BearmanE D Thomas
Dec 1, 1988·Proceedings of the Society for Experimental Biology and Medicine·Y ShimamotoA Khan
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RodriguezJ E Romaguera
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W S VelasquezF Cabanillas
Jan 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P W JohnsonT A Lister
Jun 15, 1996·Lancet·G MeloniF Mandelli
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T DemirerW I Bensinger
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J JohansenR E Champlin
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C GuglielmiF Chauvin
Feb 20, 1999·American Journal of Clinical Oncology·N HaimM Ben-Shahar
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C HudisL Norton
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H MoskowitzA D Zelenetz

❮ Previous
Next ❯

Citations

Aug 19, 2008·Current Oncology Reports·Vaishalee Padgaonkar Kenkre, Sonali M Smith
Oct 16, 2015·Leukemia Research·Geoffrey L UyDaniel C Link
Aug 27, 2002·Cytotherapy·S M SmithK van Besien
May 19, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koen Van BesienRichard Champlin
Oct 27, 2006·Oral Oncology·Dalal Abdullah Al-HakeemStephen Porter
Dec 17, 2016·Journal of Clinical and Experimental Hematopathology : JCEH·Eisei Kondo
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Issa F KhouriRichard E Champlin
Jan 17, 2003·Leukemia·F Ravandi, K van Besien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.